The FDA approved Polatuzumab vedotin for medical use on April 19, 2023, for adult patients with previously untreated diffuse large B-cell lymphoma, to be used in combination with other cancer medications.

Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma, a type of cancer originating from B lymphocytes, which are a kind of blood cell. This medication is administered for cases that are either previously untreated or for those that have recurred or not responded to at least one prior therapy. It is also an option for patients who are not eligible for a stem cell transplant.

Polatuzumab vedotin is available as 140mg injection for intravenous use to be administered by your healthcare provider. Your doctor will decide the most suitable dosage for your case according to your age and physical circumstances.

Polatuzumab vedotin is associated with several very common side effects. Patients may experience respiratory issues such as pneumonia, runny nose, sneezing, sore throat, and cough, indicative of either lung infection or upper respiratory tract infection. Peripheral neuropathy symptoms like numbness, tingling, burning sensations, pain, discomfort, weakness, and difficulty walking are also common. Other frequent side effects include fever, cough, vomiting, and gastrointestinal disturbances like diarrhea, constipation, mucositis (soreness or inflammation of the mouth and gut), nausea, and abdominal pain. Patients may also feel fatigued, have a decreased appetite leading to weight loss, and experience infusion-related reactions. Additional side effects can include the common cold, hair loss, and changes in blood test results.

Polatuzumab vedotin is not recommended to take this medication if you are allergic to Polatuzumab vedotin or its components. Also, this medication is not recommended for anyone under 18 years old. Before starting this medication, you must inform your doctor if you have any active infection. Also, inform your doctor if you have recently been vaccinated or plan to receive a vaccination shortly. Additionally, make sure to tell your doctor if you have any kidney, liver, or heart problems or any other underlying health issues before taking this medication. A detailed overview of your medication history and medical background is crucial for safe and effective treatment.

Patients using Polatuzumab vedotin should be aware of several precautions: It's not recommended for pregnant women due to risks to the fetus. Breastfeeding mothers should avoid it, as it can be transferred to the infant through breast milk. Those with lung conditions, especially infections, need to be cautious because pneumonia is a frequent side effect. Individuals with liver issues should consult their doctor, as the medication can affect liver function. Alcohol consumption should be avoided during treatment to prevent additional liver stress. Lastly, if you experience side effects like dizziness or fatigue, it's advised not to drive or operate machinery until these symptoms subside.

If you are taking Polatuzumab vedotin, it is crucial to regularly monitor your lung and liver functions with your doctor due to potential side effects. Both women and men should use effective contraception during treatment. Women should continue using birth control for at least nine months after the final dose of Polatuzumab vedotin, while men should do so for six months after completing treatment to avoid risks to their partners who may become pregnant. It's essential to consult with your doctor about the best contraceptive methods and inform them before you decide to stop using contraception. Additionally, male patients should be aware that Polatuzumab vedotin may impact fertility, so it is advisable to avoid fathering a child for six months after treatment and discuss sperm preservation options with your doctor before starting the medication.

1. Roche Products Limited, Electronic Medical Compendium (EMC),[Revised on Apr 2022][Accessed on Jan 2024] https://www.medicines.org.uk/emc/files/pil.11028.pdf 

2. Roche Products Limited, Inc, Food and Drug Safety Administration (FDA), [Revised on Apr 2023] [Accessed on Jan 2024] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761121s008lbl.pdf 

3. KD Tripathi, Essentials of Medical Pharmacology, Chemotherapy For Neoplastic Diseases, 7th edition, 2013, 930.

4. Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Pharmacotherapy for Neoplastic Diseases, 12th edition, 2011, 1206.

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.